Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
17 Firms Get Approval for Cymbalta Generics, June Listing Eyed
The Ministry of Health, Labor and Welfare (MHLW) on February 15 approved generic versions of Shionogi’s antidepressant Cymbalta (duloxetine) from 17 companies (40 products) towards the next round of reimbursement listings in June. Eisai’s insomnia med Lunesta (eszopiclone) drew generic…
To read the full story
Related Article
- Aloxi Authorized Generic Now Available Ahead of Gx Contenders
September 8, 2021
- 9 Drugs Face Generic Entries, AGx Debuts for 2 Brands: June Listing
June 17, 2021
- Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
- Will Cymbalta, E Keppra Face Generic Competition This Year? Vesicare, Aloxi Too?
January 20, 2021
REGULATORY
- Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…